Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer

A. Ciarmiello, S. Del Vecchio, P. Silvestro, M. I. Potena, M. V. Carriera, R. Thomas, G. Botti, G. D'Aiuto, M. Salvatore

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Purpose: Since we have previously shown that the efflux rate of technetium 99m (99mTc) sestamibi, a transport substrate of P-glycoprotein (Pgp), is directly correlated with Pgp levels in untreated breast carcinoma, we tested whether tumor clearance of 99mTc-sestamibi may be predictive of therapeutic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Patients and Methods: Thirty-nine patients with stage III disease, median tumor diameter 5.8 cm (range, 3 to 10) were enrolled onto this prospective clinical trial and underwent 99mTc-sestamibi scan before neoadjuvant chemotherapy. Patients were injected intravenously (IV) with 740 MBq of 99mTc-sestamibi; a 15-minute dynamic study was performed, and static planar images were obtained at 0.5, 1, 2, and 4 hours. The time to half clearance of 99mTc-sestamibi was calculated in each patient from decay corrected time-activity curves using a monoexponential fitting. Patients were treated with epirubicin 150 mg/m2 IV every 2 weeks for three courses and then underwent surgery within 3 weeks from the completion of chemotherapy. Residual tumor was assessed by pathologic examination of mastectomy specimens. Results: Seventeen of 39 patients showed a rapid tumor clearance of 99mTc-sestamibi (time to half clearance [t( 1/4 )] ≤ 204 minutes) and 15 of these 17 (88%) showed a highly cellular macroscopic residual tumor at histology that indicated lack of tumor response to neoadjuvant chemotherapy. In contrast, only eight of 22 (36%) with prolonged retention of 99mTc-sestamibi (t( 1/4 ) > 204 minutes) showed residual macroscopic tumor at histology (Fisher's exact test, P <.01). Conclusion: A rapid tumor clearance of 99mTc-sestamibi may predict lack of tumor response to neoadjuvant chemotherapy with drugs affected by the multidrug- resistant phenotype in patients with locally advanced breast carcinoma.

Original languageEnglish
Pages (from-to)1677-1683
Number of pages7
JournalJournal of Clinical Oncology
Volume16
Issue number5
Publication statusPublished - May 1998

Fingerprint

Technetium Tc 99m Sestamibi
Breast Neoplasms
Drug Therapy
Neoplasms
Residual Neoplasm
P-Glycoprotein
Histology
Epirubicin
Mastectomy
Clinical Trials
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ciarmiello, A., Del Vecchio, S., Silvestro, P., Potena, M. I., Carriera, M. V., Thomas, R., ... Salvatore, M. (1998). Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology, 16(5), 1677-1683.

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. / Ciarmiello, A.; Del Vecchio, S.; Silvestro, P.; Potena, M. I.; Carriera, M. V.; Thomas, R.; Botti, G.; D'Aiuto, G.; Salvatore, M.

In: Journal of Clinical Oncology, Vol. 16, No. 5, 05.1998, p. 1677-1683.

Research output: Contribution to journalArticle

Ciarmiello, A, Del Vecchio, S, Silvestro, P, Potena, MI, Carriera, MV, Thomas, R, Botti, G, D'Aiuto, G & Salvatore, M 1998, 'Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer', Journal of Clinical Oncology, vol. 16, no. 5, pp. 1677-1683.
Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriera MV, Thomas R et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology. 1998 May;16(5):1677-1683.
Ciarmiello, A. ; Del Vecchio, S. ; Silvestro, P. ; Potena, M. I. ; Carriera, M. V. ; Thomas, R. ; Botti, G. ; D'Aiuto, G. ; Salvatore, M. / Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 5. pp. 1677-1683.
@article{541074694e174b27946b9f3bc8098f3f,
title = "Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer",
abstract = "Purpose: Since we have previously shown that the efflux rate of technetium 99m (99mTc) sestamibi, a transport substrate of P-glycoprotein (Pgp), is directly correlated with Pgp levels in untreated breast carcinoma, we tested whether tumor clearance of 99mTc-sestamibi may be predictive of therapeutic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Patients and Methods: Thirty-nine patients with stage III disease, median tumor diameter 5.8 cm (range, 3 to 10) were enrolled onto this prospective clinical trial and underwent 99mTc-sestamibi scan before neoadjuvant chemotherapy. Patients were injected intravenously (IV) with 740 MBq of 99mTc-sestamibi; a 15-minute dynamic study was performed, and static planar images were obtained at 0.5, 1, 2, and 4 hours. The time to half clearance of 99mTc-sestamibi was calculated in each patient from decay corrected time-activity curves using a monoexponential fitting. Patients were treated with epirubicin 150 mg/m2 IV every 2 weeks for three courses and then underwent surgery within 3 weeks from the completion of chemotherapy. Residual tumor was assessed by pathologic examination of mastectomy specimens. Results: Seventeen of 39 patients showed a rapid tumor clearance of 99mTc-sestamibi (time to half clearance [t( 1/4 )] ≤ 204 minutes) and 15 of these 17 (88{\%}) showed a highly cellular macroscopic residual tumor at histology that indicated lack of tumor response to neoadjuvant chemotherapy. In contrast, only eight of 22 (36{\%}) with prolonged retention of 99mTc-sestamibi (t( 1/4 ) > 204 minutes) showed residual macroscopic tumor at histology (Fisher's exact test, P <.01). Conclusion: A rapid tumor clearance of 99mTc-sestamibi may predict lack of tumor response to neoadjuvant chemotherapy with drugs affected by the multidrug- resistant phenotype in patients with locally advanced breast carcinoma.",
author = "A. Ciarmiello and {Del Vecchio}, S. and P. Silvestro and Potena, {M. I.} and Carriera, {M. V.} and R. Thomas and G. Botti and G. D'Aiuto and M. Salvatore",
year = "1998",
month = "5",
language = "English",
volume = "16",
pages = "1677--1683",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer

AU - Ciarmiello, A.

AU - Del Vecchio, S.

AU - Silvestro, P.

AU - Potena, M. I.

AU - Carriera, M. V.

AU - Thomas, R.

AU - Botti, G.

AU - D'Aiuto, G.

AU - Salvatore, M.

PY - 1998/5

Y1 - 1998/5

N2 - Purpose: Since we have previously shown that the efflux rate of technetium 99m (99mTc) sestamibi, a transport substrate of P-glycoprotein (Pgp), is directly correlated with Pgp levels in untreated breast carcinoma, we tested whether tumor clearance of 99mTc-sestamibi may be predictive of therapeutic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Patients and Methods: Thirty-nine patients with stage III disease, median tumor diameter 5.8 cm (range, 3 to 10) were enrolled onto this prospective clinical trial and underwent 99mTc-sestamibi scan before neoadjuvant chemotherapy. Patients were injected intravenously (IV) with 740 MBq of 99mTc-sestamibi; a 15-minute dynamic study was performed, and static planar images were obtained at 0.5, 1, 2, and 4 hours. The time to half clearance of 99mTc-sestamibi was calculated in each patient from decay corrected time-activity curves using a monoexponential fitting. Patients were treated with epirubicin 150 mg/m2 IV every 2 weeks for three courses and then underwent surgery within 3 weeks from the completion of chemotherapy. Residual tumor was assessed by pathologic examination of mastectomy specimens. Results: Seventeen of 39 patients showed a rapid tumor clearance of 99mTc-sestamibi (time to half clearance [t( 1/4 )] ≤ 204 minutes) and 15 of these 17 (88%) showed a highly cellular macroscopic residual tumor at histology that indicated lack of tumor response to neoadjuvant chemotherapy. In contrast, only eight of 22 (36%) with prolonged retention of 99mTc-sestamibi (t( 1/4 ) > 204 minutes) showed residual macroscopic tumor at histology (Fisher's exact test, P <.01). Conclusion: A rapid tumor clearance of 99mTc-sestamibi may predict lack of tumor response to neoadjuvant chemotherapy with drugs affected by the multidrug- resistant phenotype in patients with locally advanced breast carcinoma.

AB - Purpose: Since we have previously shown that the efflux rate of technetium 99m (99mTc) sestamibi, a transport substrate of P-glycoprotein (Pgp), is directly correlated with Pgp levels in untreated breast carcinoma, we tested whether tumor clearance of 99mTc-sestamibi may be predictive of therapeutic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Patients and Methods: Thirty-nine patients with stage III disease, median tumor diameter 5.8 cm (range, 3 to 10) were enrolled onto this prospective clinical trial and underwent 99mTc-sestamibi scan before neoadjuvant chemotherapy. Patients were injected intravenously (IV) with 740 MBq of 99mTc-sestamibi; a 15-minute dynamic study was performed, and static planar images were obtained at 0.5, 1, 2, and 4 hours. The time to half clearance of 99mTc-sestamibi was calculated in each patient from decay corrected time-activity curves using a monoexponential fitting. Patients were treated with epirubicin 150 mg/m2 IV every 2 weeks for three courses and then underwent surgery within 3 weeks from the completion of chemotherapy. Residual tumor was assessed by pathologic examination of mastectomy specimens. Results: Seventeen of 39 patients showed a rapid tumor clearance of 99mTc-sestamibi (time to half clearance [t( 1/4 )] ≤ 204 minutes) and 15 of these 17 (88%) showed a highly cellular macroscopic residual tumor at histology that indicated lack of tumor response to neoadjuvant chemotherapy. In contrast, only eight of 22 (36%) with prolonged retention of 99mTc-sestamibi (t( 1/4 ) > 204 minutes) showed residual macroscopic tumor at histology (Fisher's exact test, P <.01). Conclusion: A rapid tumor clearance of 99mTc-sestamibi may predict lack of tumor response to neoadjuvant chemotherapy with drugs affected by the multidrug- resistant phenotype in patients with locally advanced breast carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0031804471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031804471&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 1677

EP - 1683

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -